Deep Longevity to discuss research on aging clocks at the Kinexum meeting with NIH and FDA
Kinexum brings together the leaders in aging biomarkers together with the FDA and NIH to discuss the role of biological clocks and other biomarkers of aging in regulatory development
Credit: Kinexum (http://www.kinexum.com/)
Monday, 7th of September, 2020 (Hong Kong 9.00AM) — Deep Longevity, Inc, recently acquired by Regent Pacific (HK:0575), a company developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels today announced that its Chief Science Officer, Dr. Polina Mamoshina will present the research on deep aging clocks at the Kinexum webinar titled “The Role of Biological Clocks and Other Biomarkers of Aging in Regulatory Development”.
“Advances on biomarkers of aging have exploded in recent years. Conversion of this progress into surrogate endpoints that could be used by regulators to approve longevity products has yet to occur. Conventional validation of aging biomarkers with outcome trials could take decades. This webinar combines leading researchers in aging biomarkers with a preeminent expert at the FDA for the start of a continuing conversation that we hope will accelerate the use of aging biomarkers in the regulatory and clinical development of therapeutic interventions”, said Thomas Seoh, Executive Vice President of the Kitalys Institute
The field of aging research is rapidly evolving, gaining credibility, and producing clinically-useful results. Biomarkers of aging dubbed “aging clocks” and AI-powered aging clocks developed using deep learning dubbed “deep aging clocks” are gaining mainstream acceptance. These aging clocks may be used in clinical trials for patient enrollment, stratification, hypothesis generation, as an inexpensive way to check which data type may be affected by the intervention, testing of the disease and longevity interventions, for as well as in a broad range of other applications. Many of these applications are discussed in a recent review paper by Deep Longevity titled “Deep biomarkers of aging and longevity: from research to applications”.
Deep Longevity scientists are the original inventors of the “deep aging clocks”, multimodal biomarkers of aging developed using deep learning techniques with multiple granted patents. They recently published deep hematological aging clocks, deep transcriptomic and proteomic aging clocks, deep microbiomic aging clocks, and contributed to the development of the photographic aging clocks.
“We are now witnessing a rapid evolution of aging and longevity research with major advances made in both diagnostics, interventions, and clinical trials. The longevity industry is coming of age and there needs to be a constant dialogue between the funders, academics, companies, and regulators. We are very happy to take part in this dialogue to ensure that the inventions can be translated into clinical practice and consumer use in the most credible and impactful way. We are thankful to Kinexum and Kitalys Institute for bringing together these high-profile leaders”, said Alex Zhavoronkov, PhD, founder and Chief Longevity Officer of Deep Longevity, a Regent Pacific company.
About Deep Longevity
Deep Longevity has been acquired by Regent Pacific (HK:0575), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other experts AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.
About Regent Pacific (HK: 0575)
Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.